Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person AKT1 E17K gain-of-function mutant is expected to phosphoryla...
| Class:Id | Summation:2399980 |
|---|---|
| _displayName | AKT1 E17K gain-of-function mutant is expected to phosphoryla... |
| _timestamp | 2012-07-13 15:11:09 |
| created | [InstanceEdit:2399979] Orlic-Milacic, M, 2012-07-13 |
| literatureReference | [LiteratureReference:199381] TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling [LiteratureReference:199857] Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway |
| text | AKT1 E17K gain-of-function mutant is expected to phosphorylate TSC2 and inhibit it, like the wild-type AKT (Inoki et al. 2002, Manning et al. 2002), but this has not been experimentally tested. |
| (summation) | [Reaction:2399982] AKT1 E17K mutant phosphorylates TSC2, inhibiting it [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by AKT1 E17K gain-of-function mutant is expected to phosphoryla... (2399980)
